<DOC>
	<DOCNO>NCT00002447</DOCNO>
	<brief_summary>The purpose study compare 2 anti-HIV drug combination .</brief_summary>
	<brief_title>A Study Compare Two Anti-HIV Drug Combinations</brief_title>
	<detailed_description>Patients stratify HIV RNA : 5,000-75,000 v great 75,000 copies/ml Amplicor assay . Patients randomize two arm . Arm A receives SQV plus RTV plus two NRTIs . Arm B receive EFV plus two NRTIs . Patients must take dose approximately time every day . Patients option take daily dose AM PM . Patients evaluate change plasma HIV RNA level CD4/CD8 count adverse experience laboratory determination . Evaluations make every 4-8 week Week 48 . Patients continue beyond Week 48 reach Weeks 60 , 72 , 84 , common study closure , see week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are HIVpositive . Have viral load least 5,000 copies/ml CD4 cell count least 75 cells/mm3 . Are least 18 . Are able complete study . Exclusion Criteria Patients eligible study : Have take antiHIV medication 2 week . Are pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2001</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Saquinavir</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Dosage Forms</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>efavirenz</keyword>
</DOC>